一品红(300723) - 2024 Q4 - 年度业绩预告

Financial Performance - The company expects a net profit loss of approximately 472.26 million RMB for the year 2024, compared to a profit of 184.61 million RMB in the same period last year[3] - The company's revenue and gross profit margin have decreased compared to the previous year, despite an increase in overall product shipment volume[5] - Non-recurring losses are expected to impact net profit by approximately 295 million RMB, primarily due to medical insurance refunds and goodwill impairment[6] R&D and Product Development - R&D expenses are projected to exceed 20% of revenue in 2024, with a focus on innovative products such as AR882 and APH01727[5] - AR882 has received Fast Track Designation from the FDA and is currently in Phase III clinical trials[5] Impairments and Financial Adjustments - The company plans to recognize a goodwill impairment of approximately 11.03 million RMB and asset impairment between 25 million to 35 million RMB[6] - The company is in the process of transferring patents and technology related to a flu recombinant protein vaccine project with a subsidiary[6] Financial Reporting - The financial data presented is preliminary and has not been audited by an accounting firm, with final figures to be disclosed in the 2024 annual report[7]